{"id":"W2246998135","doi":"","title":"AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Interim analysis; Internal medicine; Phases of clinical research; Renal cell carcinoma; Oncology; Gastroenterology; Neutropenia; Pharmacology; Urology; Surgery; Toxicity; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002103814,0.001216776,0.001667731,0.0004961421,0.0004542739,0.0008670432,0.0008980412,0.001361121,0.004110146],"category_scores_gemma":[0.0009375456,0.0004441117,0.0008127359,0.0003938948,0.0005623933,0.0006247793,0.0003037511,0.002273865,0.001105158],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009532492,"about_ca_system_score_gemma":0.001209248,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001006878,"about_ca_topic_score_gemma":0.002620571,"domain_scores_codex":[0.9995735,0.0001940904,0.00002283006,0.00004231451,0.00005906438,0.0001080273],"domain_scores_gemma":[0.9990991,0.0001973885,0.0001632188,0.00005348464,0.00005084531,0.0004359293],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5797469,0.03690682,0.01419941,0.001520238,0.0022039,0.0009195076,0.0002330114,0.002914179,0.06102395,0.0004997546,0.02010171,0.2797307],"study_design_scores_gemma":[0.5759925,0.367494,0.0309927,0.00007718656,0.0008256161,0.001310481,0.00004186922,0.001942436,0.01153357,0.0002365046,0.009512539,0.00004059916],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9727311,0.01206907,0.00110035,0.00165615,0.0002786948,0.002986974,0.003976057,0.0002990048,0.004902591],"genre_scores_gemma":[0.9702388,0.006286406,0.002680391,0.001723207,0.0004259253,0.002276018,0.01074632,0.0000609481,0.005561966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004110146,"threshold_uncertainty_score":0.01374984,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06798462123839182,"score_gpt":0.3577161289842715,"score_spread":0.2897315077458797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}